History Suggests These 3 Stocks Are Due for a Major Rebound

The article argues Pfizer, General Mills, and United Parcel Service could rebound from sizeable drawdowns of roughly 50% to 60%, citing temporary headwinds rather than structural damage. Pfizer faces GLP-1 and patent-expiration pressure, General Mills is navigating inflation and changing consumer preferences, and UPS is executing a turnaround aimed at improving revenue per piece and profitability. The piece also highlights attractive dividend yields of 6.5% for Pfizer, 7% for General Mills, and 6.6% for UPS while investors wait.

Analysis

The common setup across all three names is not “cheap stock” so much as balance-sheet-funded patience meeting a market that is pricing in permanent impairment. That usually creates the best entry points when the underlying franchise still has distribution, pricing power, or R&D optionality — but the key is that the rerating only happens once the market believes the earnings trough is behind us, not when management first says so. In that sense, these are all duration trades with different clocks: PFE is a multi-year pipeline reset, GIS is a 2-4 quarter margin/volume repair, and UPS is a 4-6 quarter network optimization story with a more visible inflection window.

The second-order winner is not the obvious peer set; it is suppliers and competitors that can exploit temporary share vacuums. In healthcare, patent-cliff pressure can force PFE to overpay for assets or partnerships, which is constructive for smaller biotech monetization but dilutive if execution slips. In consumer staples, weaker private-label substitution is the real threat to GIS — if the trade-down consumer does not come back, brand investment can simply defend share without restoring margin. In logistics, UPS’s push to improve revenue per piece is effectively a tax on low-yield volume, which can benefit niche carriers and specialized B2B transport firms that can hold pricing while UPS exits marginal freight.

The contrarian view is that the market may be over-discounting the permanence of these headwinds because each company has a credible path to “good enough” rather than heroic growth. For PFE, the issue is not whether it becomes a great compounder; it is whether pipeline cadence plus capital returns can stabilize earnings enough to make 6%+ yield investors stop treating it like a melting ice cube. For GIS and UPS, the more important variable is operating leverage: if input costs normalize and management avoids chasing low-quality volume, earnings can rebound faster than revenue, creating sharp upside re-ratings from depressed multiples.

Catalyst timing matters. Near term, all three can stay cheap if macro data weakens or if clinical/operating updates disappoint; but over the next 6-12 months, each has a discrete checkpoint where the market will reassess whether the trough is real. The setup favors buying gradually into weakness rather than front-running a single headline, because the upside is path-dependent and the drawdowns can remain shallow but prolonged before the inflection is accepted.

Key Decisions for Investors

• Initiate a staggered long PFE position over the next 4-8 weeks; target a 12-18 month hold for pipeline/stabilization rerating, with dividend carry as downside support and upside tied to sentiment normalizing before full patent-cliff clarity.
• Buy GIS on weakness as a 6-12 month turnaround trade; size modestly because the risk is a longer-than-expected demand reset, but reward is a compressed valuation snapping back if organic sales and margins re-accelerate.
• Accumulate UPS only if management commentary confirms revenue-per-piece gains persist for another quarter; best as a 2H26 catalyst trade with higher beta to execution, but attractive if the market is still pricing in a permanent volume impairment.
• Pair trade: long PFE / short a basket of cash-burner biotech names with no near-term commercial optionality; the long leg offers yield and balance-sheet support while the short leg captures the market’s preference for quality cash flow over speculative pipelines.
• For more tactical exposure, sell cash-secured puts on GIS or UPS 1-2 strikes below current levels and 3-6 months out; this monetizes elevated implied skepticism while allowing entry at a better basis if the turnaround thesis takes longer.